BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that for the second year in a row, Forbes has named the Company to its America’s “Best Employers” list. The list recognizes the top 300 midsized employers and top 500 large employers. Results are based on anonymous survey responses from 30,000 U.S. employees, with the most weighted factor being how likely they were to recommend their organizations to others.
“Receiving this recognition for the second consecutive year is a testament to our efforts to advance investments in developing our people, and we are pleased to see that reflected in strong feedback from employees,” said Michelle Graham, Senior Vice President and Chief Human Resources Officer, PAREXEL. “We strive to attract, develop and retain top talent at PAREXEL to best serve our clients in bringing new, life-saving treatments to patients around the globe.”
PAREXEL is committed to investing in its people and fostering an environment in which employees are engaged and empowered to do their best work in an effort to deliver for clients. To further this goal, PAREXEL provides best-in-class training programs and professional growth opportunities, as well as flexible work options. Recently, PAREXEL’s training program was recognized in Training magazine’s “Training Top 125” for developing creative and effective learning and development initiatives for its global workforce.
About the Forbes America’s Best Employers List Methodology
Now in its third year, the Forbes ranking of America’s Best Employers is drawn from an online survey of more than 30,000 employees at companies with at least 1,000 people in their U.S. operations. Participation in the survey was voluntary, and respondents were recruited from thousands of sources to maximize reach and representation. The mix of respondents (gender, age, region, and ethnicity) in the sample represents American employees. Each employee surveyed was asked to rank both his own employer and other employers in the same industry sector. Employees were also asked how likely they were to recommend their organization to friends or family; this was the most important factor in determining a company’s ranking on the list.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.